4 min read

SCOPE 2023 – Bringing Focus onto the Patient

This year's SCOPE Summit focused on the hybridization of research facilitating better evidence generation through patient-centric study design & execution.

This month, UBC sponsored and presented at the Summit for Clinical Operations Executives (SCOPE) in Orlando, Florida. UBC’s presentations were focused on the utility of enriching real-world data (RWD) across both clinical trials and observational research. This fit into a larger theme that emerged at SCOPE – the hybridization of research facilitates better evidence generation and revolves around patient-centric study design and execution.

A prominent part of this over the last couple of years has been a focus on diversity in clinical trials, leading to recent diversity guidelines from the FDA and initiatives to increase diversity from the NIH. This generates a more complete picture of a product’s safety and effectiveness but also leads to improved health outcomes for minority populations who are now part of the drug development process.

This initiative for diversity is moving hand-in-hand with decentralization techniques aimed at engaging patients from diverse backgrounds more effectively. A key failure in achieving diversity in the past was not knowing how to best engage with patients that wouldn’t fit the profile for a traditional site-only study. Patients have now shifted their expectations on how and when they will engage with healthcare professionals. They are used to video calls, portals, and mobile messaging. This adds complexity to the development of protocols and study conduct but greatly benefits the ability to recruit patients (particularly in rare disease), reduce patient drop-out, and generate more comprehensive evidence for a product.

Pragmatic trials are another key component of this. Pragmatic trials are designed to evaluate treatments in real-world settings. Pragmatic trials often involve larger and more diverse patient populations than traditional randomized controlled trials (RCTs) and are designed to assess how treatments perform in the context of routine clinical practice. Pragmatic trials can also evaluate the cost-effectiveness of treatments and provide insights into how treatments can be integrated into existing healthcare systems. This enables them to be used to evaluate the safety and efficacy of treatments in populations that are often excluded or under-represented from traditional RCTs, such as pregnant women, racial or ethnic minorities, and the elderly.

The innovation that has exploded in both clinical trials and observational studies in recent years anchors back to this patient-centric approach. UBC is committed to our Patients First mentality in the design and execution of our research programs. Through initiatives like patient-mediated electronic medical record release and a distinct team dedicated to optimal patient recruitment and engagement practices, UBC fosters smarter, evidence-based decisions for better patient access, outcomes, and evidence generation. To get in touch, click here.

About the Author

Lee Randall is a Senior Project Manager in Peri- & Post-Approval Services at UBC. He has over 22 years of experience in the pharmaceutical industry, both academic and public. His experience includes Phase I, II, III, and Non-Interventional with therapeutic indications including, but not limited to, Hematology, Oncology (solid tumor, hematological malignancies, genomic profiling), Infectious Disease, and Rheumatology.

Other Recent Posts

5 min read

UBC and Thread Expand SitePlus Offering and Active Studies with BioPharma Sponsors to Optimize Evidence Generation

This augments the central site model with additional research services and tech to widen recruitment and improves site and patient experience.
3 min read

UBC Appoints Anthony Luttenberger Chief Commercial Officer

Biopharma services industry veteran brings decades of experience spanning late-stage, clinical trials, & post-approval commercial support.
1 min read

UBC Listed as a Citeline Awards Finalist for Excellence in RWE

UBC is once again a finalist for the Citeline Awards, with our 2024 nomination coming in the Excellence in RWE category.

Thank You for Connecting with UBC

Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.

What You Can Expect Next

Lorem ipsum dolor sit amet consectetur. Cras aliquam erat eget magna sollicitudin.

Get Ready to Change Your Business

Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.

Service Request

Bekki Bracken Brown

President & Chief Executive Officer

Bekki Bracken Brown serves as the President and CEO of UBC, guiding the company’s mission and values, including the improvement of access for patients to receive better outcomes. She oversees all aspects of UBC, such as operations, business growth strategy, sales and marketing, and acquisition support.

With over 20 years of industry experience, Ms. Brown brings knowledge from a successful career in senior management from her tenure at Quintiles, INC Research, and, most recently, with Syneos Health. She’s been a member of the North Carolina BIO Board of Directors since 2019. She is also a member of the Healthcare Businesswomen’s Association — Southeast Chapter and CHIEF, an organization that supports women executive leaders. Ms. Brown earned her bachelor’s degree at Duke University.